Research & Development

Programme Hospitalier de Recherche Clinique National (PHRCN) [National Clinical Hospital Research Programme] Preconception

This clinical research project is led by the MAP (“Medically Assisted Procreation”) of the Bluets centre (Paris 12th arrondissement) and MatriceLAB Innove. This is a randomised, controlled protocol evaluating the utility of immune testing of uterine receptivity for women starting their course of PMA. This study started in February 2015.
Know more about this program

Better understanding of immune mechanisms

In order to best advise patients and propose the best adapted treatments to their immunological profile, we must first understand their mechanisms of action. To be able to accomplish this we need to compare the results of our biomarkers before and after treatment. One can obtain this information if patients with a dysregulated profile accept performing a second test under proposed treatment.

Current understanding of immune balance during embryo transplantation is constantly evolving. New mechanisms are updated, which identifies new potential therapeutic targets. We study new targets to add to our receptivity testing in order to improve our diagnostics. With these new targets, we can develop dysregulation profiles and propose even more-relevant therapeutic strategies.

Payment by Health Insurance

In the context of our innovation process, we are working to demonstrate the medical benefit of this testing with health authorities in order to be reimbursed by health insurance. Your cooperation is vital in this context. We also invite you to communicate with us at the start of your next IVF attempt, giving the transfer date and the number of embryos transferred (fresh or frozen). In the case of pregnancy, we would also like to understand the course (any possible complications, etc.) as well as the delivery duration, the sex and weight of the child at birth.

Automating and certifying the uterine receptivity immunity test

In order to respond to the increasing demands of clinicians and patients, more of whom would like to conduct immunological testing of uterine receptivity before IVF, we have successively automated the various stages of our testing. This also allows us to develop new testing platforms in Paris.

We are working in parallel to develop software to directly create a patient file, accessible by the physician, the patient and the laboratory, thus permitting follow-up on the testing and to directly gather the notes (expected implementation at the end of 2020).

This software will simplify the processes and reduce the time needed to obtain results.

All the development steps are managed in adherence with European standards, and our goal is to obtain ISO 13485 certification  by the start of 2021.